A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Selepressin (Primary)
  • Indications Septic shock
  • Focus Registrational; Therapeutic Use
  • Acronyms SEPSIS-ACT
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Apr 2019 to 1 Feb 2018.
    • 08 Sep 2017 The study has been suspended in Denmark.
    • 29 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top